Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) saw a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 56,618 shares, a decline of 78.8% from the April 15th total of 267,352 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 158,455 shares, the days-to-cover ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Cyclerion Therapeutics Stock Performance

Shares of Cyclerion Therapeutics stock traded up $0.03 during midday trading on Friday, reaching $3.12. 17,068 shares of the company’s stock traded hands, compared to its average volume of 4,079,237. The company has a market cap of $13.49 million, a PE ratio of -2.29 and a beta of 1.80. The stock has a 50 day moving average of $2.66 and a 200-day moving average of $1.90. Cyclerion Therapeutics has a 12 month low of $1.03 and a 12 month high of $8.48.

Cyclerion Therapeutics (NASDAQ:CYCN) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%. On average, equities analysts anticipate that Cyclerion Therapeutics will post -1.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 75.62% of the stock is currently owned by institutional investors.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.